Most likely, intracellular molecular defects specific for disturbed granulopoiesis in CN patients (39) and not G-CSF therapy per se, is responsible for the acquisition of CSF3R mutations in some HSC clones and clonal overgrowth of these clones. The gene discussed is CSF3; the disease is cyclic hematopoiesis.